Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601342 | 1.00 | MEN1 (0.60) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL6603205 | 0.89 | MEN1 (0.77) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL6603213 | 0.89 | MEN1 (0.77) | MEN1KMT2ATP53MAPTSMN1; SMN2 | |
| SCHEMBL6606061 | 0.88 | MEN1 (0.60) | MEN1KMT2ATP53 | |
| SCHEMBL6606056 | 0.88 | MEN1 (0.60) | MEN1KMT2ATP53 | |
| SCHEMBL6600171 | 0.80 | — | — | |
| SCHEMBL6600169 | 0.80 | — | — | |
| SCHEMBL6606316 | 0.79 | — | — | |
| SCHEMBL6606320 | 0.79 | — | — | |
| SCHEMBL6604629 | 0.78 | LMNA (0.69) | MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | claimed |
| EP-0800511-B1 | FUNCTIONALISED PHOTOINITIATORS, DERIVATIVES AND MACROMERS THEREFROM AND THEIR USE | NOVARTIS AG (CH) | 2000-01-26 | — | — | EP | claimed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019113110-A2 | MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA | VANDERKLISH PETER (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| CN-1420114-A | 2,3-disubstd. -4(3H)-quinazolones | PFIZER (US) | 2003-05-28 | — | — | CN | disclosed |
| CN-1103772-C | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 2003-03-26 | — | — | CN | disclosed |
| US-6306864-B1 | CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303615-B1 | FOR THERAPY AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, CONVULSIONS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| CN-1248248-A | Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists | PFIZER PROD INC (US) | 2000-03-22 | — | — | CN | disclosed |
| EP-0968194-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| CN-1218464-A | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | MEN1 2335/4885KMT2A 568/4885TP53 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.